Several pan-Raf inhibitors showed promising results in preclinical models of cancers bearing RAS mutations, including melanoma [54], acute myeloid leukemia (AML) [59], colorectal cancer [60], multiple myeloma [61,62], pancreatic cancer [63] and thyroid cancer [64], and are currently under clinical evaluation. The gene discussed is RAF1; the disease is melanoma.